Cancer (Neoplasms) in North America
How Cancer (Neoplasms) affects 3 countries in North America.
| # | Country | Share (%) |
|---|
Across the 3 countries in North America tracked in this dataset, cancer (neoplasms) accounts for an average of 28.5% of total deaths. The regional average of 28.5% is notably higher than the global average of 17.5%, indicating that North America carries a disproportionate burden of cancer (neoplasms) mortality relative to the world. In North America, cancer (neoplasms) mortality is notably elevated relative to other high-income regions, reflecting the effects of high substance use, metabolic risk factors, and inequities in healthcare access despite substantial overall health spending.
North America has among the world's highest health expenditure per capita, yet faces distinctive mortality challenges including the opioid epidemic, firearm violence, rising metabolic disease, and significant health disparities linked to race and income. Within North America, significant variation exists. Bermuda records the highest share at 31.6% of total deaths, while United States has the lowest at 22.88%. This 8.8 percentage-point spread reflects differences in exposure, health system capacity, demographic structure, and risk factor prevalence across the region. Country-level pages provide detailed mortality breakdowns, time trends, and comparisons for each nation.
Cancer prevention spans primary prevention (reducing exposure to carcinogens), secondary prevention (screening for early detection), and tertiary prevention (treatment to prevent recurrence). Tobacco control remains the highest-impact single intervention. HPV vaccination can eliminate cervical cancer and substantially reduce oropharyngeal cancers. Hepatitis B vaccination prevents liver cancer. Screening programmes for breast, cervical, and colorectal cancers are proven to reduce mortality in well-resourced settings. Expanding access to pathology, surgery, radiotherapy, and essential chemotherapy in low- and middle-income countries is critical to reducing the global cancer mortality gap.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for cancer (neoplasms) in North America, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
The cause-of-death categories used on this page follow the Global Burden of Disease cause hierarchy, a standardized classification that groups individual ICD-coded causes into clinically meaningful categories. The "share of deaths" metric shows what percentage of all deaths in a given country or region are attributed to cancer (neoplasms). A rising share does not necessarily mean more people are dying from this cause — it may reflect success in reducing competing causes of death. Always examine both absolute rates and shares for a complete picture of mortality patterns in North America.